TrialCancer medicine2018

A prospective Phase II study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK trial.

Shigeyoshi Iwamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.